Wockhardt said that it will market a patented drug used in treatment of osteoporosis in the country.
Switzerland-based DSM Nutritional Products, the patent holder of Bonistein, has licensed the drug to Wockhardt, the Indian biotech company said in a statement.
Habil Khorakiwala, chairman, Wockhardt, said: "This will strengthen our orthopaedic portfolio."
In India, the market for osteoporosis formulations market is over Rs 250 crore, as per data from ORG IMS. This market is growing at 19 per cent.
The biotech major plans to launch the medicine in mid-2009.